Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs Layla

Belle Health
Graded #48

Higher grade

vs+6.099999999999994
Layla
Graded #101

Lower grade

The verdict

Belle Health takes it — 77/100 to 70.9/100.

Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBelle Health +26
92
66
Dose & formulationLayla +24
72
96
Clinical oversightLayla +5
71
76
Labs & monitoringBelle Health +20
72
52
FulfillmentBelle Health +20
85
65
Contract termsEven
55
55
Belle Health · left barLayla · right bar

The numbers

MetricBelle HealthLayla
WeighScore77/10070.9/100
GradeC+C
Scorecard rank#48#101
Semaglutide$119/mo$237/mo (all doses, compounded)
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$199/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Belle Health

Graded #48 · C+

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Layla

Graded #101 · C

Strengths

  • Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
  • Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
  • Quiz-based intake with fast three to five day shipping

Where it loses points

  • Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
  • States served are not published on the site
  • Support phone line uses a UK format, and the compounding pharmacy is not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard